International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2024) Mar 5 - Mar 9, 2024 Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristic… Supporting Materials Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials 1.8 MB
Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials 1.8 MB